In an extraordinary display of precision medicine, a multidisciplinary team at the University of North Carolina (UNC) School of Medicine has fast-tracked a personalized treatment for twin girls battling a unique form of juvenile Batten disease. The girls, diagnosed with CLN3 disease, possessed a genetic variant never before observed, prompting researchers to develop a custom therapy tailored specifically to their genetic makeup.
Collaborating with researchers at the University of Michigan, the team focused on antisense oligonucleotides (ASOs)—short RNA molecules capable of targeting specific gene sites to correct expression and restore protein function. Using cells recovered from the girls' skin biopsies, scientists tested various ASOs to identify the most potent candidate for recovering expression from the mutated gene. The resulting customized treatment, named Zebronkysen, was developed and manufactured in record time.
Navigating the regulatory landscape for such an individualized investigational drug is typically a lengthy process. However, the team successfully obtained approvals from the FDA and institutional review boards in just over a year. In June 2024, the twins received their first doses of the ASO drug via spinal tap in a first-of-its-kind "N-of-2" clinical trial.
While it is too early to determine the long-term effects, the primary goal is to restore the function of the CLN3 gene and prevent further neurodegeneration. This pioneering study not only offers hope to the affected family but also serves as a vital proof-of-concept for developing personalized treatments for other patients with rare genetic variants. The success of this rapid bench-to-bedside transition highlights the transformative potential of collaborative, individualized medicine in combating ultra-rare pediatric disorders.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.